Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDillistone Regulatory News (DSG)

Share Price Information for Dillistone (DSG)

Share Price is delayed by 15 minutes
Get Live Data
11.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (9.091%)
Market Cap: £4.07m
DSG Live PriceLast checked at - London Stock Exchange

Intraday Dillistone Share Chart

Issue of Options

11 Feb 2021 07:00

RNS Number : 6821O
Dillistone Group PLC
11 February 2021
 

 

Dillistone Group Plc

("Dillistone", the "Company" or the "Group")

Issue of Options

Dillistone Group Plc, the AIM quoted supplier of software and services to recruiters, announces the grant on 10 February 2021 of options over 500,000 Ordinary Shares of 5p each in Dillistone (the "Options") to certain of its Directors and other members of staff.

Options over 450,000 Ordinary Shares were granted, exercisable within 3 to 10 years but subject to performance conditions, to six Directors and other senior managers under the Company's LTIP scheme with an exercise price of 22p per share. Details of the grants to Directors are set out below. The remuneration committee has approved the grant of options and the thresholds which are challenging.

 

Status

LTIP option grant at 22p

No. Options held post Grant including Savings Related Share Options

Current Shareholding in Company

Jason Starr

Director

50,000

70,000

3,577,591

Julie Pomeroy

Director

50,000

93,146

63,733

Alex James

Director

50,000

86,250

112,744

Simon Warburton

Director

50,000

150,646

77,290

Paul Mather

Director

50,000

206,292*

32,177

Steve Hammond

Director

50,000

136,250

0

Total

 

300,000

742,584

3,863,535

* Paul Mather's interest includes options over 58,146 shares granted to his spouse as an employee.

In addition, options over 50,000 Ordinary Shares with an exercise price of 22p per share were granted, exercisable within 3 to 10 years but without performance conditions, to other members of staff.

Following this grant, the Company has 1,806,337 Ordinary Shares under option, representing 9.18% of the current issued share capital of the Company.

Commenting on the grant, Giles Fearnley, Non Executive Chairman at Dillistone said:

"This grant of options is to incentivise staff as the Group focuses on returning to profitability with its new products, the benefits of recent restructuring and as we emerge from the pandemic."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Enquiries:

Dillistone Group Plc

 

 Via Walbrook PR

Jason Starr

Chief Executive

 

Julie Pomeroy

Finance Director

 

 

 

 

WH Ireland Limited (Nominated adviser)

 

 

Chris Fielding

Managing Director,

Corporate Finance

020 7220 1650

 

 

 

Walbrook PR

 

 

Tom Cooper / Nick Rome

 

020 7933 8780

 

 

dillistone@walbrookpr.com

 

Notes to Editors:

Dillistone Group Plc is a leader in the supply and support of software and services to recruiters. Dillistone operates through the Ikiru People brand.

The Group develops, markets and supports the Talentis, FileFinder, Infinity, Midoffice, ISV and GatedTalent products.

Dillistone was admitted to AIM, a market operated by the London Stock Exchange plc, in June 2006. The Group employs around 90 people globally with offices in Basingstoke, Southampton, New Jersey and Sydney.

 

How Talentis can be used in Executive Search: https://www.talentis.global/recruitment-software/executive-search-software/

How Talentis is a transformational recruiting software: https://www.talentis.global/recruitment-software/next-generation-recruitment-software/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBRGDDXGBDGBG
Date   Source Headline
7th May 20267:00 amRNSFinal Results & Investor Presentation
24th Apr 20267:00 amRNSNotice of Final Results & Investor Presentation
9th Mar 20262:44 pmRNSHolding(s) in Company
9th Mar 20262:44 pmRNSHolding(s) in Company
9th Mar 20262:23 pmRNSHolding(s) in Company
9th Mar 20262:23 pmRNSHolding(s) in Company
2nd Mar 20263:08 pmRNSHolding(s) in Company
25th Feb 202611:40 amRNSHolding(s) in Company
25th Feb 202610:09 amRNSHolding(s) in Company
23rd Feb 20262:28 pmRNSResult of GM & Directorate Change
11th Feb 202612:59 pmRNSHolding(s) in Company
5th Feb 202611:28 amRNSResult of Placing and Subscription
4th Feb 20264:47 pmRNSProposed Placing and Subscription
30th Sep 20257:00 amRNSInterim Results & Investor Presentation
11th Sep 20257:00 amRNSNotice of Interim Results & Investor Presentation
4th Jun 202511:50 amRNSResult of AGM
4th Jun 20257:01 amRNSAGM Statement
4th Jun 20257:00 amRNSRelated party loan
9th May 202511:32 amRNSDirectorate Declaration
8th Apr 20257:00 amRNSFinal Results & Investor Presentation
3rd Apr 20257:00 amRNSNotice of Results & Investor Presentation
5th Feb 20257:00 amRNSTrading Update & Notice of Results
4th Dec 20247:00 amRNS-ROpenAI powered Interview Simulation Platform
17th Sep 20247:00 amRNSInterim Results & Investor Presentation
11th Sep 20247:00 amRNSNotice of Results & Investor Presentation
2nd Sep 20249:45 amRNSHolding(s) in Company
29th Aug 20248:30 amRNSHolding(s) in Company
23rd Aug 20247:00 amRNSTrading update and Fund Raising
15th Jul 20247:00 amRNSChange of Adviser
12th Jun 20241:40 pmRNSResult of AGM
12th Jun 20247:00 amRNSAGM Statement
25th Apr 20247:00 amRNSFinal Results & Investor Presentation
22nd Apr 20247:00 amRNSNotice of Results & Investor Presentation
9th Apr 20247:00 amRNSBlock listing Interim Review
30th Jan 20247:00 amRNSTrading Update & Notice of Results
9th Oct 20237:00 amRNSBlock listing Interim Review
26th Sep 20237:00 amRNSInterim Results & Investor Presentations
18th Sep 20237:00 amRNSNotice of Results & Investor Presentations
13th Jun 20231:18 pmRNSResult of AGM
13th Jun 20237:00 amRNSAGM Statement
25th Apr 20237:00 amRNSFinal Results & Investor Presentation
11th Apr 20237:00 amRNSBlock listing Interim Review
30th Mar 20237:00 amRNSContract & Notice of Results
2nd Feb 20237:00 amRNSTrading Update & Notice of Results
7th Nov 20227:00 amRNSDirector Dealings
10th Oct 20227:00 amRNSBlock listing Interim Review
26th Sep 20227:01 amRNSDirectorate Changes
26th Sep 20227:00 amRNSInterim Results & Investor Presentation
20th Sep 20227:00 amRNSNotice of Results & Investor Presentation
16th Jun 20228:00 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.